Skip to content
Enspryng(satralizumab)
Enspryng (satralizumab) is an antibody pharmaceutical. Satralizumab was first approved as Enspryng on 2020-08-14. It is used to treat neuromyelitis optica in the USA. It has been approved in Europe to treat neuromyelitis optica.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
eye diseasesD005128
immune system diseasesD007154
Trade Name
FDA
EMA
Enspryng
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Satralizumab
Tradename
Proper name
Company
Number
Date
Products
Enspryngsatralizumab-mwgeGenentechN-761149 RX2020-08-14
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
enspryngBiologic Licensing Application2020-08-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
neuromyelitis opticaEFO_0004256D009471G36.0
Agency Specific
FDA
EMA
Expiration
Code
satralizumab, Enspryng, Genentech, Inc.
2027-08-14Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L04: Immunosuppressants
L04A: Immunosuppressants
L04AC: Interleukin inhibitors
L04AC19: Satralizumab
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuromyelitis opticaD009471EFO_0004256G36.0415
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myasthenia gravisD009157EFO_0004991G70.011
Autoimmune diseases of the nervous systemD02027411
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary arterial hypertensionD00008102911
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSATRALIZUMAB
INNsatralizumab
Description
Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID1535963-91-7
RxCUI
ChEMBL IDCHEMBL3833307
ChEBI ID
PubChem CID
DrugBankDB15762
UNII IDYB18NF020M (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Enspryng - Roche
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 331 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7,259 adverse events reported
View more details